Paeds Cases · rheumatology-musculoskeletal-and-sports
Explain juvenile dermatomyositis to a worried parent — OSCE
OSCE communication and shared-planning station: explaining the diagnosis of juvenile dermatomyositis to a parent, the reason for the muscle enzymes and magnetic resonance imaging, the corticosteroid and methotrexate treatment, the risk of calcinosis and why early treatment matters, and the follow-up and multidisciplinary plan, with empathy and honesty and without overpromising.
On this page
Study tools
Target exams
What the candidate must do
Acknowledge the mother's worry, confirm her understanding, and explain juvenile dermatomyositis in plain language as an inflammation of the skin and muscles caused by an overactive immune system. Explain that the rash around the eyes and over the knuckles and the leg weakness are two parts of the same illness, and that the blood test showing a raised muscle enzyme called creatine kinase confirms that the muscles are inflamed. Describe a magnetic resonance imaging scan as a safe way to see the inflammation without a biopsy in most cases. [1]
Outline the treatment honestly: strong anti-inflammatory medicine called corticosteroids, given first by a short drip in hospital and then as tablets, together with a weekly medicine called methotrexate that allows the steroids to be tapered more safely. Name the common side effects the family should expect and watch for — lowered immunity with infection risk, stomach protection, calcium and vitamin D for the bones, and the need for regular blood tests — and explain the multidisciplinary team of rheumatology, physiotherapy, occupational therapy, dermatology and psychology. [2]
Address the prognosis and the calcinosis risk without overpromising: most children improve substantially with modern treatment, but the illness is serious and lasts months to years, and the most important reason to treat aggressively now is to prevent hard calcium lumps under the skin called calcinosis that can be painful and hard to reverse once they form. Agree a clear follow-up plan, give written information and a contact for questions, and offer psychology support for the child and family. [1] [2] [3]
References3ShowHide
- [1]Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis, 2017.PMID 29079590
- [2]Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet, 2016.PMID 26645190
- [3]Hoeltzel MF, Oberle EJ, Robinson AB, et al. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep, 2014.PMID 25366934